Who Paid My Doc
Lisa Barker
Hospice and Palliative Medicine Land O Lakes, FL Medical Doctor
NPI 1205807500 CMS profile 191048
2061 Collier Pkwy, Land O Lakes, FL 34639
General payments
$98
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Lisa Barker of Land O Lakes, FL is reported in the CMS Open Payments database as having received $98 across 5 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $98 | 5 |
Beside peers
- Lisa Barker
- Florida median
- Middle half of Florida
- National median
In program year 2025, general payments to Lisa Barker were reported at $0. Among 84,641 Florida profiles paid that year, the median was $195 and the middle half received between $59 and $690.
Show as a table
| Year | Lisa Barker | Florida median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $197 | $63–$719 | $163 |
| 2020 | $0 | $126 | $38–$436 | $114 |
| 2021 | $98 | $151 | $45–$537 | $132 |
| 2022 | $0 | $175 | $53–$607 | $149 |
| 2023 | $0 | $183 | $57–$637 | $160 |
| 2024 | $0 | $185 | $56–$647 | $164 |
| 2025 | $0 | $195 | $59–$690 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 15 drugsPart D claims
1,385
Drug cost
$82,731
Branded share of claims
44.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxycontin Oxycodone Hcl | Brand | 33 | $28,930 | |
| Fentanyl | Generic | 120 | $15,008 | |
| Oxycodone Hcl | Generic | 267 | $8,801 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 190 | $8,012 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 242 | $7,686 | |
| Morphine Sulfate Er Morphine Sulfate | Brand | 150 | $5,962 | |
| Methadone Hcl | Generic | 169 | $3,810 | |
| Hydromorphone Hcl | Generic | 56 | $2,061 | |
| Morphine Sulfate | Generic | 50 | $1,086 | |
| Doxazosin Mesylate | Generic | 15 | $543 |
The 10 drugs with the highest cost, of 15 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 200 Part D prescribers listed as Surgery; they describe a distribution and say nothing about conduct.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hospice and Palliative Medicine in Florida
Related records
Hospice and Palliative Medicine in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Hospice and Palliative Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.